Metabolic research
Retatrutide
Lyophilized metabolic research compound
Retatrutide is a metabolic research peptide studied as a triple agonist at GIP, GLP-1, and glucagon receptors. Published studies provide receptor-pharmacology and dose-ranging context for this molecular class.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
연구 맥락
Retatrutide 연구 프로필
Retatrutide is studied as a single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. Research commonly compares receptor potency, signaling balance, pharmacokinetics, glucose and lipid markers, energy expenditure, and body-mass endpoints across cell, animal, and controlled human studies. Its main distinction is the addition of glucagon-receptor activity to the incretin pathways represented by GIP and GLP-1. This makes it useful when a project needs a triple-agonist reference rather than the dual-receptor profile associated with tirzepatide. Published human trial results describe the investigated pharmaceutical molecule and do not establish the identity or performance of a catalog batch.
제안된 기전
Proposed triple agonism at the GIP, GLP-1, and glucagon receptors. GIPR and GLP-1R signaling is associated with glucose-dependent insulin secretion and appetite-related pathways, while GCGR activity adds hepatic and energy-expenditure signaling. The balance of activity across all three receptors is central to the molecule.
연구에서 보고된 효과
- Cell and animal studies report activation of all three receptor pathways, reduced food intake, improved glucose handling, and increased energy expenditure.
- Phase 2 human studies reported dose-dependent reductions in body weight and improvements in selected cardiometabolic markers.
- Gastrointestinal adverse events and treatment discontinuations were also reported in controlled human studies.
일반적인 연구 평가변수
Receptor potency and bias, cyclic AMP response, food intake, energy expenditure, glucose and insulin markers, lipids, body mass, pharmacokinetics, and tolerability observations.
근거와 한계
Mechanistic, animal, and controlled human evidence exists for the investigational pharmaceutical molecule. Those results do not verify a separate catalog batch or guarantee an experimental result.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
Metabolic Research peptide
Tirzepatide
Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.
- 형태
- Lyophilized powder
- 수량
- 30 mg
-
Metabolic Research peptide
